High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study
Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs
Early initiation of combination antiretroviral therapy (cART), at higher CD4 cell counts, prevents disease progression and reduces sexual transmission of human immunodeficiency virus (HIV). We describe the temporal trends in CD4 cell counts at the start of cART in adults from low-income, lower-middle-income, upper-middle-income, and high-income countries (LICs, LMICs, UMICs, and HICs, respectively).
Study finds more than half of patients worldwide don’t access HIV treatment until immune systems are severely compromised
Identification of misdiagnosed HIV clients in an Early Access to ART for All implementation study in Eswatini
Rapid diagnostic testing has made HIV diagnosis and subsequent treatment more accessible. However, multiple factors, including improper implementation of testing strategies and clerical errors, have been reported to lead to HIV misdiagnosis. The World Health Organization has recommended HIV retesting prior to antiretroviral therapy (ART) initiation which has become pertinent with scaling up of Early Access to ART for All (EAAA). In this analysis, misdiagnosed clients are identified from a subgroup of clients enrolled in EAAA implementation study in Swaziland.
The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all people living with HIV.
Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality
The much-discussed HIV ‘cascade of care’ has demonstrated marked loss between HIV diagnosis, linkage and initiation of antiretroviral treatment (ART), compromising mortality and morbidity benefits to the individual, as well as public health prevention impact. As large-scale programmes provide more long-term data, opportunities have arisen to reduces losses across the cascade.
A lead physician with the World Health Organization (WHO) says the Geneva-based group may change its guidelines for when HIV-infected individuals should start antiretroviral treatment (ART), a move that could potentially affect millions.